Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Ralf Gutzmer

1-34 of 34 results

View this query on the Wikidata Query Service
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

scientific article
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

scientific article
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

scientific article
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

scientific article published on 18 February 2016
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

scientific article
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

scientific article
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

scientific article published on 8 March 2017
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

scientific article published on 18 May 2017
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

scientific article published on 12 September 2018
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity

scientific article published on 16 February 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

scientific article published on 16 February 2017
Basal cell carcinoma-treatments for the commonest skin cancer

scientific article
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

scientific article published on 02 December 2019
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma

scientific article
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

article
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors

scientific article published on 17 November 2018
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

scientific article published on 27 February 2018
Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma.

scientific article
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

scientific article published on 26 February 2019
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

scientific article published on 13 February 2018
Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma

scientific article published on 16 October 2015
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management.

scientific article published on 23 May 2019
Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook

scientific article published on 24 October 2019
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

scientific article published on 03 October 2019
Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma

scientific article published on 01 June 2019
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG

scientific article published on 01 May 2020
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

scientific article published on 19 June 2020
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

scientific article published on 21 November 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

scientific article published on 18 September 2020
Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD-1-Antikörper beim metastasierten Melanom - ein Update

scientific article published on 01 June 2020
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update

scientific article published on 03 June 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

scientific article published on 01 October 2020
Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

Paulina is supported by:

About Paulina

Help